United States · Business magazines · Quartz
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

Detailed summary
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)



